REVERSE ENGINEERING MOTHER NATURE TO CREATE NATURAL PLANT-BASED PRODUCTS THAT HEAL & DELIGHT

Sustainability – Superior Quality – Legal – Cheaper – PCT Patents
 

ESENSE LAB “Creating the Virtual Plant” – by producing superior quality terpene profiles

ESENSE LAB is a technology and research & development pharmaceutical company specialising in the commercialisation of the phytochemical profiling of plants

Specialist expertise in “Reverse Engineering” and plant profiling via patented (PCT) techniques combining genetics, mRNA, protein expression and phytochemical profiles, thereby generating a single comprehensive model of each target Plant.

Terpenes are the major constituents of plant resin and essential oils extracted from plants that produce the distinctive flavour and smell

Short pathway to commercialisation with distribution pending fulfilment

First vertical is a high growth and rapidly expanding global opportunity

First mover advantage: intention of commencing commercial production of a high demand product with superior quality to any other currently available

Globally, the consumption of essential oils is growing at over 10% annually and is estimated at US$6 billion in 2015

LEAD MANAGER TO THE OFFER – OTSANA CAPITAL

GENERAL INFORMATION 

Esense Lab’s goal is to achieve whole-plant phytochemical profiles of a vast variety of targeted plants.  The Company’s first vertical in the commercialisation of their unique and disruptive technology is the profiling of cannabis and terpenes, in one of the most rapidly growing markets world wide. This approach will also be applied by Esense Lab to other lucrative target plants; such as Ginseng, Saffron, Sandalwood, and other rare and medicinal plants or spices.

Sustainability

The company wishes to serve as an alternative to natural occurring resources and ease the pressure of wild populations of rare plants.  Simultaneously, we aim to make the essence of these plants accessible and affordable to the broad market.

The Prospectus is subject to an exposure period commencing on 6 December 2016, which is expected to end on 20 December 2016 (unless extended by ASIC). Investors are advised that:

• applications will not be processed until after the exposure period;
• no preference will be conferred on applications received in the exposure period; and

the purpose of the exposure period is to enable the Prospectus to be examined by market participants before the raising of funds. The examination of the disclosure document may result in the identification of deficiencies in the disclosure document and, in these circumstances, any application that has been received may need to be dealt with in accordance with section 724 of the Corporations Act (which will involve either returning the application money or giving the applicants a supplementary or replacement prospectus and the opportunity to withdraw their applications).